Skip to main content
Astria Therapeutics, Inc. logo

Astria Therapeutics, Inc. — Investor Relations & Filings

Ticker · ATXS ISIN · US04635X1028 US Manufacturing
Open in API
Filings indexed 602 across all filing types
Latest filing 2026-01-23 Director's Dealing
Country US United States of America
Listing US ATXS

About Astria Therapeutics, Inc.

https://astriatx.com/

Astria Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for allergic and immunologic diseases. The company's mission is to provide life-changing treatments to patients and their families. Its lead product candidate, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein being developed as a potential long-acting, preventative treatment for Hereditary Angioedema (HAE). The company has reported positive initial proof-of-concept results from its ALPHA-STAR Phase 1b/2 clinical trial for STAR-0215. Astria Therapeutics is guided by patient needs to develop differentiated therapeutics that address significant unmet medical needs.

Recent filings

Filing Released Lang Actions
4 Filing
Director's Dealing
2026-01-23 English
S-8 POS Filing
Regulatory Filings Classification · 100% confidence The document is a Post-Effective Amendment to multiple Registration Statements on Form S-8 filed with the SEC. It details the deregistration of securities following a merger, specifically terminating the effectiveness of previously filed Registration Statements and removing unsold securities from registration. The document is a regulatory filing related to securities registration and deregistration, not a financial report, earnings release, or management discussion. It does not contain financial statements or detailed financial analysis but is a formal SEC filing about registration status changes. Therefore, it fits best under Regulatory Filings (RNS). The document length (8582 characters) and content confirm it is not a brief announcement but a formal regulatory amendment filing.
2026-01-23 English
8-K Filing
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is a Form 8-K current report filed with the SEC, dated January 21, 2026. It reports the submission of matters to a vote of security holders at a special meeting, specifically the approval of a merger proposal and a compensation proposal related to the merger. The document includes detailed voting results and references a definitive proxy statement. The content focuses on the official results of shareholder votes at a meeting, which aligns with the category of Declaration of Voting Results & Voting Rights Announcements (DVA). The document is not a full annual or quarterly report, nor is it a proxy solicitation or a merger filing itself, but rather the official announcement of voting outcomes. Therefore, the appropriate classification is DVA with high confidence.
2026-01-21 English
FORM 8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC by Astria Therapeutics, Inc. It reports on a merger agreement with BioCryst Pharmaceuticals, including references to a definitive proxy statement related to the merger and legal complaints filed against the company and its board. The document includes forward-looking statements caution and detailed information about where to find the proxy statement and registration statement. The content focuses on merger-related disclosures and legal proceedings rather than financial results or management discussion. The document is not a full annual or quarterly report, nor is it a proxy solicitation itself but references the proxy statement. It is a current report on Form 8-K, which is a regulatory filing used to disclose material events. Therefore, the best classification is Regulatory Filings (RNS), as it is a general regulatory announcement that does not fit other specific categories like M&A filings or legal proceedings report, since it primarily reports the event and references other filings rather than being the merger filing or legal report itself.
2025-12-23 English
425 Filing
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a Current Report pursuant to the Securities Exchange Act of 1934. It discusses a merger agreement, related proxy statement filings, and legal proceedings related to the merger. The document does not contain financial statements or detailed financial analysis but rather provides updates on corporate events and legal matters. It also references filings like the proxy statement and registration statement but does not include those reports themselves. The primary content is about merger-related events and legal complaints, which fits the category of a Regulatory Filing (RNS) as it is a general regulatory announcement that does not fit into more specific categories like M&A filings or legal proceedings reports. The document length is over 10,000 characters, so it is not a brief announcement but a substantive regulatory filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2025-12-23 English
DEFM14A Filing
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a definitive proxy statement filed pursuant to Schedule 14A under the Securities Exchange Act of 1934. It is clearly labeled as a proxy statement and includes detailed information about a proposed merger, voting proposals, and instructions for stockholders to vote. The document is not an announcement of a report but the actual solicitation material for a shareholder vote. It contains detailed merger information, voting proposals, and recommendations from the board of directors. This fits the definition of Proxy Solicitation & Information Statement (PSI).
2025-12-18 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.